Navigation Links
Oncothyreon to receive milestone payment
Date:5/14/2008

uture prospects, this release contains statements that are forward looking, including statements related to payments Oncothyreon may expect to receive; the therapeutic and commercial potential of Stimuvax; future clinical development plans; the details of clinical trials; and the anticipated future size of the market for Stimuvax. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, the safety and efficacy of Stimuvax, and the possibility of future milestone and royalty payments. There can be no guarantee that the results of earlier trials will be predictive of either safety or efficacy in future trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed by Oncothyreon I
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon Reports First Quarter 2008 Financial Results
2. Oncothyreon files investigational new drug application for PX-866 oncology compound
3. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
4. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
5. Oncothyreon announces effectiveness of shelf registration statement
6. Oncothyreon announces issuance of patent for PX-867
7. Oncothyreon to present at upcoming investment conferences
8. Oncothyreon reports full year and fourth quarter 2007 financial results
9. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
10. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
11. Oncothyreon launches new corporate website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Biofertilizers stimulate microbial activities in soil. ... phosphorous through the activities in the soil or in ... to the stress on reducing environmental pollution and on ... defines and segments the bio fertilizers market with analysis ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Eckert & ... Mass Spectrometry (AMS) services to the pharmaceutical and biotech ... joined the company in the position of Director of ... of broad and valuable experience in drug metabolism and ...
(Date:1/22/2015)... 22, 2015 GEA Niro Soavi the ... laboratory homogenizer, the PandaPLUS 2000, which is ideal for ... and cell disruption . This compact laboratory homogenizer ... juices, liquid food, food additives and ingredients as well ...
(Date:1/22/2015)... laboratory information management systems market is a rapidly growing ... due to factors such as rising pressure to comply ... and increasing government support for adoption of HCIT solutions ... the market focus on technological advancements to further the ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4
... Corp.,(Nasdaq: GENZ ) announced today that it ... for the treatment of Hunter syndrome.,Elaprase is an ... Inc., and Genzyme is commercializing the product in ... with Shire. Genzyme intends,to launch Elaprase this quarter, ...
... Inc. (Nasdaq:,BIOD) today announced that Solomon Steiner, Chairman and CEO ... 2007 in San,Francisco, CA on October 11th at 11:00 AM ... live audio webcast of the,presentation in the investor relations section ... presentation will be available for,14 days. About Biodel Inc. ...
... new products, Skin Optimizer and Hyaluronic Acid Complex, promote ... skin and ... Formulas, recognized in,July by Nutrition Business Journal, selected BioCell Collagen ... the,effectiveness of two new Jarrow Formulas products -- Skin Optimizer ...
Cached Biology Technology:Genzyme Receives Approval to Market Elaprase(R) in Japan 2Genzyme Receives Approval to Market Elaprase(R) in Japan 3Genzyme Receives Approval to Market Elaprase(R) in Japan 4Biodel Inc. to Present at BIO InvestorForum 2007 Conference on October 11, 2007 2Jarrow Formulas Launches New Products Featuring BioCell Collagen II(R) 2
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., the ... study that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four hundred years ... as a meeting place for peoples from different continents. This ...
(Date:12/17/2014)... FORT BELVOIR, Va. , Dec. 15, 2014 ... make it easier to detect and prevent counterfeit microcircuits ... the agency started performing an in-house microcircuit anti-counterfeit initiative ... of purchased microcircuits while increasing their reliability throughout the ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in this market ... applications. Chemical sensors help in recording of patient data ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... Clinicians and scientists working in the Southampton Centre ... Southampton,s University Hospitals Trust (SUHT) and the University ... the city,s world-leading nutrition and respiratory research facilities. ... the Government,s record 800m investment in NHS and ...
... agriculture, causing famine and increasing consumer food costs. Now, researchers at the ... completed two drought simulators designed to test the effects of water deficiency ... Research and Extension Center east of Columbia. , , ... , , ...
... Medicine has been awarded a $3.4 million grant over four ... the National Institutes of Health (NIH) to begin the largest ... for disease is revealed in a lab, and then entered ... in the clinical care setting. Using DNA and ...
Cached Biology News:Southampton researchers awarded $28 million to progress pioneering nutrition and respiratory research 2University of Missouri completes first drought simulator 2University of Missouri completes first drought simulator 3Mount Sinai receives $3.4 million for largest study of personalized medicine in the clinical setting 2Mount Sinai receives $3.4 million for largest study of personalized medicine in the clinical setting 3
... Shakers combine high durability and performance ... The patented triple-counterbalanced heavy-duty mechanism ... run with heavy out-of-balance loads. ... contamination. The heavy stainless steel ...
... The Cellject Uno Electroporator is a ... producing optimum efficiencies in bacterial and ... selects one of two voltages and ... four mm cuvettes. On pressing the ...
MOUSE ANTI GTP BINDING PROTEIN...
... coli containing a clone of the human Topoisomerase ... II alters the topological state of nucleic acids ... transient break which generates a separate DNA helix ... DNA passage mechanism, the enzyme can relax negatively ...
Biology Products: